within Pharmacolibrary.Drugs.ATC.A;

model A10BJ02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.55,
    Cl             = 0.9 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 0.6 / 1000000,
    adminCount     = 1,
    Vd             = 0.013,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Liraglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist used primarily for the treatment of type 2 diabetes mellitus and as an anti-obesity agent. It is approved for use in adults and pediatric patients for glycemic control and for chronic weight management.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters determined in adult healthy subjects and patients with type 2 diabetes following subcutaneous administration.</p><h4>References</h4><ol><li><p>Jacobsen, LV, et al., &amp; Ingwersen, SH (2016). Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics. <i>Clinical pharmacokinetics</i> 55(6) 657–672. DOI:<a href=&quot;https://doi.org/10.1007/s40262-015-0343-6&quot;>10.1007/s40262-015-0343-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26597252/&quot;>https://pubmed.ncbi.nlm.nih.gov/26597252</a></p></li><li><p>Lee, TS, et al., &amp; Shin, S (2023). Novel LC-MS/MS analysis of the GLP-1 analog semaglutide with its application to pharmacokinetics and brain distribution studies in rats. <i>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</i> 1221 123688–None. DOI:<a href=&quot;https://doi.org/10.1016/j.jchromb.2023.123688&quot;>10.1016/j.jchromb.2023.123688</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36989942/&quot;>https://pubmed.ncbi.nlm.nih.gov/36989942</a></p></li><li><p>Bucheit, JD, et al., &amp; Sisson, EM (2020). Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist. <i>Diabetes technology &amp; therapeutics</i> 22(1) 10–18. DOI:<a href=&quot;https://doi.org/10.1089/dia.2019.0185&quot;>10.1089/dia.2019.0185</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31436480/&quot;>https://pubmed.ncbi.nlm.nih.gov/31436480</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A10BJ02;
